Metabolomic signature of type 1 diabetes-induced sensory loss and nerve damage in diabetic neuropathy

Diabetic-induced peripheral neuropathy (DPN) is a diabetic late complication. The molecular mechanisms underlying the pathophysiology of nerve damage & sensory loss remain largely unclear. Recently, alterations in metabolic flux have gained attention a basis for organ damage in diabetes; however, peripheral sensory neurons have not been adequately analyzed. In the present study, we attempted to delineate the role of alteration of metabolic pathways in relation to nerve damage & sensory loss. We employed STZ-injected mouse model of type1 diabetes. To investigate the progression of DPN by behavioral measurements of sensitivity to thermal & mechanical stimuli and quantitative assessment of intraepidermal nerve fiber density. We employed a MS-based screen to address alterations in levels of metabolites in peripheral sciatic nerve (SN) & amino acids (AA) in serum over several months post-STZ administration. Although hyperglycemia & body weight changes occurred early, sensory loss & reduced intraepithelial branching of nociceptive nerves was only evident at 22 wks post-STZ. The longitudinal metabolites screen in SN demonstrated that mice at 12 and 22 wks post-STZ showed an early impairment the tricarboxylic acid. We found that levels of citric acid, ketoglutaric acid, succinic acid, fumaric acid & malic acid were observed to be significantly reduced in SN at 22 wks post-STZ. In addition, we also found the increase in levels of sorbitol & L-Lactate in SN from 12 wks post-STZ injection. AA screen in serum showed that the amino acids Val, Ile and Leu, increased more than 2-fold from 12 wks post-STZ. Similarly, the levels of Tyr, Asn, Ser, His, Ala, & Pro showed progressive increase. Our results indicate that the impaired TCA cycle metabolites in peripheral nerve is the primary cause of shunting metabolic substrate to compensatory pathways which leads to mitochondrial dysfunction & nerve damage.

💡 Research Summary

This study investigated the temporal relationship between metabolic alterations and the development of diabetic peripheral neuropathy (DPN) in a low‑dose streptozotocin (STZ) mouse model of type‑1 diabetes. Male C57BL/6J mice (7–8 weeks old) received five consecutive daily injections of STZ (60 mg/kg) to induce β‑cell loss and sustained hyperglycemia (>350 mg/dL). Blood glucose was monitored weekly, and insulin was administered subcutaneously to keep glucose levels between 350–500 mg/dL throughout the 22‑week observation period.

The authors performed longitudinal assessments at baseline, 8, 12, and 22 weeks post‑STZ. Behavioral testing included Hargreaves thermal nociception and von Frey mechanical thresholds. No significant differences were observed at 12 weeks, but by 22 weeks STZ‑treated mice displayed clear hypoalgesia: increased withdrawal latencies to heat and higher mechanical thresholds (p < 0.05). Intra‑epidermal nerve fiber density (IENFD) was quantified by CGRP immunostaining of plantar skin sections; IENFD was unchanged at 12 weeks but reduced by ~30 % at 22 weeks, confirming structural nerve loss.

Metabolomic profiling was carried out on two fronts. Sciatic nerve tissue was extracted with methanol, derivatized (methoximation followed by silylation), and analyzed by GC‑MS. Early (12 weeks) the nerve showed elevated sorbitol and L‑lactate, indicating activation of the polyol pathway and increased glycolytic flux. By 22 weeks, five key tricarboxylic acid (TCA) cycle intermediates—citrate, α‑ketoglutarate (2‑KG), succinate, fumarate, and malate—were significantly reduced (p < 0.05), suggesting impaired mitochondrial oxidative metabolism.

Serum amino acids were measured after AccQ‑Tag fluorescence labeling and UPLC‑FLD detection. Branched‑chain amino acids (BCAAs: valine, isoleucine, leucine) rose more than two‑fold from 12 weeks onward. Additional amino acids (tyrosine, asparagine, serine, histidine, alanine, proline) displayed progressive increases. Elevated BCAAs are known to reflect systemic insulin resistance and metabolic stress, and may influence neuronal protein synthesis and signaling.

Statistical analysis employed repeated‑measures ANOVA with Bonferroni correction; significance was set at p ≤ 0.05.

The authors conclude that sustained hyperglycemia first disrupts the TCA cycle in peripheral nerves, forcing glucose‑derived carbon into alternative routes (polyol pathway, lactate production). This metabolic rerouting likely precipitates mitochondrial dysfunction, oxidative stress, and ultimately axonal degeneration and sensory loss. The concurrent rise in circulating BCAAs and other amino acids provides a systemic signature of metabolic imbalance that parallels nerve pathology.

Strengths of the work include its longitudinal design, integration of functional (behavioral), structural (IENFD), and biochemical (metabolomics) data, and the use of an insulin‑controlled model that isolates hyperglycemia from insulin deficiency per se. Limitations are the lack of direct mitochondrial functional assays (e.g., oxygen consumption, ATP production), absence of DRG‑specific molecular analyses, and potential confounding effects of exogenous insulin on systemic metabolism.

Future directions suggested are: (1) direct measurement of mitochondrial respiration in sciatic nerve and DRG neurons; (2) transcriptomic/proteomic profiling of metabolic enzymes in sensory neurons; (3) therapeutic trials using TCA cycle intermediates (e.g., α‑ketoglutarate supplementation) or polyol pathway inhibitors (e.g., aldose reductase inhibitors) to test causality; and (4) validation of the identified metabolic biomarkers in human DPN cohorts for diagnostic or prognostic use.

Overall, the study provides compelling evidence that early TCA cycle impairment and subsequent metabolic shunting are central mechanisms linking chronic hyperglycemia to the onset and progression of diabetic peripheral neuropathy.